UroGen Pharma Ltd
URGN
Market Cap$195.5M
Close$
$15.60
203.6% upside
Current Fair Value
203.6% upsideUndervalued by 203.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $195.50 Million |
|---|---|
| Enterprise Value | $216.41 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.96 |
| Beta | 0.67 |
| Outstanding Shares | 47,422,119 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.45 |
|---|---|
| PEG | -4.06 |
| Price to Sales | 5.14 |
| Price to Book Ratio | -5.14 |
| Enterprise Value to Revenue | 2.36 |
| Enterprise Value to EBIT | -2.05 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.58 |
| Debt to Equity | -2.69 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About UroGen Pharma Ltd
CEO: Elizabeth Barrett